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Abstract 
Purpose: To investigate the anti-hyperlipidemic effect of Caralluma edulis and Verbena officinalis. 
Methods: Phytochemical analysis of crude extracts of Caralluma edulis (Ce.Cr) and Verbena officinalis 
(Vo.Cr) were carried out. Hyperlipidemia was induced in mice with high-fat diet (HFD, 1.25 % w/w 
cholesterol, 0.5 % w/w cholic acid and 10 % v/w coconut oil). All the groups, except the saline-treated 
group, were fed on HFD for 4 weeks (lead-in period) to induce hyperlipidemia. Thereafter, the groups 
were treated with varying doses of the plant extract for 2 weeks (treatment period) as well as 
atorvastatin (10 mg/kg) reference standard. Body weight was measured fortnightly for all groups. Total 
cholesterol (TC), triglyceride (TGs) and low density lipoprotein (LDL) were assayed using Merck 
diagnostic kits. For histopathological analysis, liver slices were fixed in 10 % formalin and embedded in 
paraffin wax and was examined with the aid of hematoxylin and eosin staining (H & E).  
Results: Caralluma edulis (Ce.Cr) contains saponins, alkaloids, tannins, phenol, glycosides, terpenoids 
and flavonoids while Verbena officinalis (Vo.Cr) tested positive for the presence of alkaloids, 
carbohydrates, flavonoids, saponins and tannins. HFD increased total cholesterol (TC), triglyceride 
(TGs), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) compared to regulator diet 
(p < 0.001). Treatment of the animals with Ce.Cr and Vo.Cr dose-dependently (500 - 1000 mg/kg) 
reduced serum TC, TGs, LDL and VLDL (p < 0.05, p < 0.01, p < 0.001, vs. HFD group) and raised high 
density lipoprotein (HDL) (p < 0.01, vs. HFD group), similar to that observed with atorvastatin (10 
mg/kg). The anti-hyperlipidemic effects of Ce.Cr and Vo.Cr were also confirmed via liver histopathology 
results, showing improved structure with no hepatocellular necrosis and fat accumulation.  
Conclusion: These results indicate that Caralluma edulis and Verbena officinalis exhibit anti-
hyperlipidemic effect; thus, the plants have therapeutic potentials for the management of lipid disorders. 
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Hyperlipidemia leads to the progression of 
various cardiovascular complications, such as 
atherosclerosis, myocardial infarction and 
hypertension [1]. Various types of lipids such as 
total cholesterol (TC), triglyceride (TGs), high 
density lipoprotein (HDL), and low density 
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lipoprotein (LDL), very low density lipoproteins 
(VLDL) cause various health problems such as 
pancreatitis and cardiovascular disorders [2]. It 
has been reported that about one fourth of the 
people suffering from myocardial infarction had 
hyperlipidemia [3]. Effective management of 
hyperlipidemia reduces the risk of cardiovascular 
events. Current therapy for hyperlipidemia 
management includes statins, fibrates, and bile 
acid sequestrates but the use of these drugs has 
been associated with many side effects. 
Medicinal plants enriched in phytochemicals 
such as tannins, saponins, flavonoids, essential 
oils and alkaloids have curative properties and 
are used in the traditional system of medicine for 
the management of various ailments [4]. 
Oxidative stress plays an important role in the 
onset of hyperlipidemia due to free radical 
generation, which leads to the further 
progression of cardiovascular diseases [5]. 
Medicinal plants being rich in antioxidant 
constituents possess profound antioxidant 
properties. 
 
Caralluma edulis commonly known as ‘’Choung’’ 
belongs to family Asclepiadaceae. Genus 
Caralluma enriched in pregnane glycosides, 
megastigmane glycosides, flavone and esters 
[6]. Caralluma edulis is known to possess 
antidiabetic [7] and antioxidant [8] properties. 
 
Verbena officinalis commonly known as 
“Vervian”, “Herb of grace” belongs to family 
Verbenaceae [9]. Verbena officinalis contain 
various irridoids such as verbenalin and 
hastatoside which possess antioxidant properties 
[10]. In the current investigation we evaluated 
anti-hyperlipidemic activity of Caralluma edulis 
and Verbena officinalis using high fat diet (HFD) 
animal model to explore their use in the 




Plant material and extraction 
 
The whole plant Caralluma edulis was purchased 
from a local market in May and the whole plant of 
Verbena officinalis was collected from Rawat, 
Islamabad, Pakistan. The plant samples were 
identified from Dr. Mushtaq Ahmad at Plant 
Sciences Department, Quaid-i-Azam University, 
Islamabad. The sample specimen bearing 
voucher number ISB-422 and ISB-270 were 
deposited to the herbarium of same department. 
The plants were thoroughly washed, shade dried 
at room temperature and coarsely ground. The 
Caralluma edulis powdered material (3 kg) was 
treated with 80 % aqueous-ethanol for seven 
days and Verbena officinalis grinded powder (2.7 
kg) was soaked in 70 % methanol for 14 days, 
with ocassional shaking and mixing. Both the 
plant materials were filtered through grade 1 
Whatmann filter paper [11]. The filtered materials 
were concentrated on rotary evaporator to obtain 
a thick semi-solid paste i.e. Caralluma edulis 
crude extract (Ce.Cr) and Verbena officinalis 
crude extract (Vo.Cr), yielding approximately 
4.67 % (w/w) and 18.66 % (w/w) respectively. 
The crude extracts were solubilized in normal 
saline. 
 
Chemicals     
    
Cholic acid and cholesterol were purchased from 
Sigma Chemicals (Germany), atorvastatin from 
Getz Pharmaceuticals, Karachi Pakistan and 
crude coconut oil procured from Marhaba lab, 
Pvt Ltd. Lahore. Analytical grade chemicals were 
used. TC, TGs and HDL diagnostic kits were 




Balb-C mice (25 - 35 g) were used in the study 
and placed at Animal House of the Riphah 
Institute of Pharmaceutical Sciences, where 
controlled environmental conditions were 
maintained at 25 ± 2°C temperature, 12 h light 
and dark cycle with free access to standard diet 
and tap water ad libitum.  Animal experiments 
were performed in accordance with “Principles of 
Laboratory Animal care” (NIH publication 85-23, 
revised 1985) [12] approved by Ethics Committee 
of Riphah Institute of Pharmaceutical Sciences 




The phytochemical analysis was performed 
according to the standard protocols [13] with 
slight modifications.  
 
Induction of hyperlipidemia  
 
Hyperlipidemia was induced by feeding on high 
fat diet (1.25 % w/w cholesterol, 0.5 % w/w cholic 
acid and 10 % v/w coconut oil with slight 
modifications [14]. The period of 4 week was 
considered as the lead-in period to induce 
hyperlipidemia in mice while in the next two week 
period treatment was done with different doses of 
plant. Body weights were measured after every 




Balb-C mice were divided into seven groups 
each consisting of six animals. Group 1 served 
as regular diet control treated orally with saline 
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(10 mL/kg). Group 2 received only HFD. Group 3 
and 4 received Ce.Cr at the dose of 500 and 
1000 mg/kg respectively along with HFD. Group 
5 and 6 received Vo.Cr at the dose 500 and 1000 
mg/kg respectively along with HFD. Group 7 
received atorvastatin dose 10 mg/kg with HFD. 
All the doses were given through oral route (p.o). 
 
Determination of hyperlipidemia 
 
The blood sample (1 mL) was collected using 
disposable syringe via cardiac puncture and 
allowed to clot at room temperature in sterile gel 
tubes for 45 min. The plasma was separated 
through centrifugation at 3000 rpm for 10 min 
and the samples were analyzed 
spectrophotometrically. TC, TGs and HDL were 
assayed using Merck diagnostic kits. LDL and 
VLDL concentrations were measured using 
Fridewald’s equations as in Eqs 1 and 2, 
respectively [15]. 
 
VLDL = (TGs)/5 ………………………… (1) 
 
LDL = TC - (HDL) - (VLDL) ................... (2) 
 
Body weight measurement 
 
Body weight was measured initially, then after 




Liver slices were fixed in 10 % formalin and 
embedded in paraffin wax and histopathological 
analysis of liver samples studied through 




Data expressed as Mean ± SEM (standard error 
of mean). Results were analyzed using one-way 
analysis of variance (ANOVA) followed by post-








The phytochemical analysis revealed that Ce.Cr 
contains saponins, alkaloids, tannin, phenol, 
glycosides, terpenoids and flavonoids. While 
Vo.Cr indicates the presence of for alkaloids, 
carbohydrates, f lavonoids, saponins and 
tannins. 
 
Effect of Ce.Cr and Vo.Cr on TC 
 
Ce.Cr and Vo.Cr dose-dependently (500 - 1000 
mg/kg) reduce the HFD-induced raise in level of 
TC (Table 1). In saline treated group, TC value 
was 92.8 ± 8.66 mg/dL. HFD treatment raised 
level of TC to 386.2 ± 21.82 mg/dL (p < 0.001 vs. 
saline group). Treatment of groups with Ce.Cr at 
the dose of 500 and 1000 mg/kg for two weeks 
reduced TC level to 305.4 ± 6.72 and 287.8 ± 
16.85 mg/dL (p < 0.01; p < 0.001 vs. HFD group) 
respectively.  Similarly Vo.Cr at 500 and 1000 
mg/kg reduced TC level from 386.2 ± 21.82 
mg/dL to 165 ± 14.47 and 116.8 ± 9.82 mg/dL (p 
< 0.001; p < 0.001 vs. HFD group) respectively. 
Atorvastatin (10 mg/kg) reduces TC level to 
161.4 ± 9.47 mg/dL (p < 0.001 vs. HFD group. 
 
Effect of Ce.Cr and Vo.Cr on TGs 
 
Ce.Cr and Vo.Cr dose-dependently (500 - 1000 
mg/kg) reduced the HFD induced increased level 
of TGs (Table 1). TGs value of saline treated 
group was 86.6 ± 6.85 mg/dL. Treatment of mice 
with HFD raised level of TGs to 162 ± 14.21 
mg/dL (p < 0.001 vs. saline group).  Ce.Cr at 
doses of 500 and 1000 mg/kg reduced TGs level 
to 139.2 ± 11.35 mg/dL and 125.4 ± 6.72 mg/dL 
respectively (p < 0.05 vs. HFD group) as shown 
in Table 1, Vo.Cr (500 and 1000 mg/kg) caused 
significant reduction in the HFD-induced 
increased level of TGs in rats plasma. In 
atorvastatin (10 mg/kg) treated group, TGs level 
value was 114.4 ± 8.08 mg/dL (p < 0.05 vs. HFD 
group). 
 
Table 1: Inhibitory effect of Caralluma edulis crude extract (Ce.Cr) and Verbena officinalis crude extract (Vo.Cr) 
against high fat diet (HFD)-induced increase in total cholesterol (TC), triglycerides (TGs), high density lipoprotein 
(HDL) and low density lipoprotein (LDL)  in mice 
 
Treatment TC (mg/dL) TGs (mg/dL) HDL(mg/dL) LDL (mg/dL) 
Saline (10 mL/kg) 92.8 ± 8.66 86.6 ± 6.85 33.4 ± 2.16 41.6 ± 7.09 
HFD 386.2 ± 21.82# 162 ± 14.21# 32 ± 2.608 317.4 ± 23.37# 
HFD + Ce.Cr (500 mg/kg)  305.4 ± 6.72** 139.2 ±11.35* 51.2 ± 2.26** 229.6 ± 6.34** 
HFD +  Ce.Cr (1000 mg/kg) 287.8 ± 16.85*** 125.4 ± 6.72* 51.8 ± 3.08** 210.6 ± 18.53*** 
HFD + Vo.Cr (500 mg/kg) 165 ± 14.47*** 148 ± 10.83* 49 ± 0.83** 86 ± 15.64*** 
HFD + Vo.Cr (1000 mg/kg) 116.8 ± 9.82*** 82.8 ± 6.39*** 50.8 ± 0.66** 49 ± 9.36*** 
HFD + Atorvastatin (10 mg/kg) 161.4 ± 9.47*** 114.4 ± 8.08* 49 ± 1.51** 89 ± 9.70*** 
Values are expressed as Mean ± SEM (n = 5); #p < 0.001 vs. saline group, **p < 0.01, ***p < 0.001 vs. HFD 
treated group; one-way ANOVA with Tukey post-hoc test 
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Effect of Ce.Cr and Vo.Cr on HDL 
 
Ce.Cr and Vo.Cr increased the level of HDL in 
dose-dependent (500 - 1000 mg/kg) manner 
(Table 1). The HDL level of saline treated group 
was 33.4 ± 2.16 mg/dL. In HFD treatment group, 
the level of HDL was 32 ± 2.608 mg/dL (p > 0.05 
vs. saline group).  Ce.Cr at dose of 500 and 1000 
mg/kg caused significant (p < 0.01 vs. HFD 
group) increase in the HDL level to 51.2 ± 2.26 
mg/dL and 51.8 ± 3.08 mg/dL respectively (p < 
0.01 vs. HFD group). Similar results were 
obtained in groups treated with Vo.Cr (500 and 
1000 mg/kg). In atorvastatin (10 mg/kg) treated 
group, HDL level value was 49 ± 1.51 mg/dL (p < 
0.01 vs. HFD group). 
 
Effect of Ce.Cr and Vo.Cr on LDL 
 
Ce.Cr and Vo.Cr dose-dependently (500 - 1000 
mg/kg) reduced the HFD-induced raise in level of 
LDL (Table 1). In saline treated group, LDL value 
was 41.6 ± 7.09 mg/dL. HFD treatment raised 
level of LDL to 317.4 ± 23.37 mg/dL (p < 0.001 
vs. saline group). Ce.Cr (500 and 1000 mg/kg) 
reduced LDL level to 229.6 ± 6.34 mg/dL (p < 
0.01 vs. HFD group) and 210.6 ± 18.53 mg/dL (p 
< 0.001 vs. HFD group) respectively. Vo.Cr (500 
and 1000 mg/kg) produced marked reduction in 
the LDL level to 86 ± 15.64 mg/dL (p < 0.001 vs. 
HFD group) and 49 ± 9.36 mg/dL (p < 0.001 vs. 
HFD group) respectively. Similarly atorvastatin 
(10 mg/kg) produced significant reduction in the 
LDL level up to 89 ± 9.70 mg/dL (p < 0.001 vs. 
HFD group). 
 
Effect of Ce.Cr and Vo.Cr on VLDL 
 
Ce.Cr and Vo.Cr dose-dependently (500 - 1000 
mg/kg) reduced the HFD induced raised in level 
of VLDL (Table 2). In saline treated group, VLDL 
value was 17 ± 1.44 mg/dL. HFD treatment 
raised level of VLDL to 32 ± 2.90 mg/dL (p < 
0.001 vs. saline group). In Ce.Cr (500 and 1000 
mg/kg) treated groups, VLDL level reduced to 
27.4 ± 2.20 mg/dL and 24.6 ± 1.28 mg/dL (p < 
0.05 vs. HFD group) respectively. Vo.Cr at dose 
of 500 and 1000 mg/kg decreased VLDL level to 
29.2 ± 2.22 mg/dL (p < 0.05 vs. HFD group) and 
16 ± 1.30 mg/dL (p < 0.001 vs. HFD group) 
respectively. Atorvastatin (10 mg/kg) reduced the 
VLDL level to 22.4 ± 1.63 mg/dL (p < 0.05 vs. 
HFD group). 
 
Table 2: Inhibitory effect of Caralluma edulis crude 
extract (Ce.Cr) and Verbena officinalis crude extract 
(Vo.Cr) against high fat diet (HFD)-induced increase in 
very low density lipoprotein (VLDL) in mice 
 
Treatment      VLDL (mg/dL) 
Saline (10 mL/kg)      17.00 ± 1.44 
HFD      32.00 ± 2.90# 
HFD + Ce.Cr (500 mg/kg)       27.40 ± 2.20* 
HFD +  Ce.Cr (1000 mg/kg)      24.60 ± 1.28* 
HFD + Vo.Cr (500 mg/kg)      29.20 ± 2.22* 
HFD + Vo.Cr (1000 mg/kg)      16.00 ± 1.30*** 
HFD + Atorvastatin (10 mg/kg)      22.40 ± 1.63* 
Values expressed as mean ± SEM (n = 5 in each 
group); #p < 0.001 vs. saline group, *p < 0.05, ***p < 
0.001 vs. HFD treated group, one-way ANOVA with 
Tukey post-hoc test 
 
Effect of Ce.Cr and Vo. Cr on body weight 
 
Ce.Cr at 500 and 1000 mg/kg reduced the body 
weight of mice, while Vo.Cr at 500 and 1000 
mg/kg doses does not cause any reduction of 
animal body weight at end of treatment as shown 




Hematoxylin and eosin staining clearly showed 
fatty liver of mice fed on HFD compared to the 
animas fed on regular diet. Deposition of fat in 
mice fed on HFD was decreased in animals 
treated with Ce.Cr (500 and 1000 mg/kg). As 
shown in Figure 1, fat deposition was not seen in 
animals treated with Vo.Cr (500 and 1000 mg/kg) 
and atorvastatin (10 mg/kg). 
 
The liver section of mice treated with saline 
group shows no fatty changes and composed of 
central vein surrounded by hepatic cords (Figure 
1A). In HFD group, the liver showed central vein 
congestion and marked fatty change (Figure 1B).  
 
Table 3: Effect of Caralluma edulis crude extract (Ce.Cr) and Verbena officinalis crude extract (Vo.Cr) on the 
body weight of high fat diet (HFD) administered mice 
 
GROUPS Body weight (g) 
0 week 2nd week 4th week 6th week 
Saline (10 mL/kg) 29.3 ± 1.17 29.6 ± 1.15 29.9 ± 1.09 30.5 ± 1.19 
HFD 31.1 ± 1.09 32.0 ± 0.84 33.6 ± 0.81 35.1 ± 1.33 
HFD + Ce.Cr (500 mg/kg) 29.7 ± 0.55 30.8 ± 0.72 31.4 ± 0.66 30.1 ± 0.86 
HFD + Ce.Cr (1000 mg/kg) 29.6 ± 0.69 30.3 ± 0.75 30.6 ± 0.70 29.2 ± 0.40 
HFD + Vo.Cr (500 mg/kg) 31.4 ± 0.80 31.9 ± 0.63 32.4 ± 0.71 32.8 ± 0.78 
HFD + Vo.Cr (1000 mg/kg) 32.6 ± 0.59 33.2 ± 0.65 33.8 ± 0.70 34.5 ± 0.46 
HFD + Atorvastatin (10mg/kg) 31.2 ± 0.88 32.4 ± 0.70 33.0 ± 0.71 33.3 ± 0.72 
    Values expressed as mean ± SEM (n = 5) 
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Figure 1: Representative micrographs (40× magnification, hematoxylin and eosin staining), showing effect of 
Caralluma edulis crude extract (Ce.Cr) and Verbena officinalis crude extract (Vo.Cr) against HFD induced 
histopathological changes in mice liver. A. Saline (10 mL/kg) treated liver tissue, showing normal central vein 
surrounded by hepatic cords with no fatty change. B. HFD intoxicated liver tissue, showing central vein 
congestion and marked fatty change. C. Ce.Cr (500 mg/kg) treated liver tissue, showing central vein congestion 
and moderate fatty change. D. Ce.Cr (1000 mg/kg) treated liver tissue, showing central vein congestion and mild 
fatty change. E. Vo.Cr (500 mg/kg) treated liver showing portal vein congestion and periportal hepatocytes drop 
out with no fatty change. F. Vo.Cr (1000 mg/kg) treated liver showing periportal hepatocytes drop out with no fatty 
change. G. Atorvastatin (10 mg/kg) treatment showing portal vein congestion and hepatocytes drop out with no 
fatty change 
 
In the Ce.Cr (500 mg/kg) treated animals, the 
liver tissue showed central vein congestion and 
moderate fatty change (Figure 1C). 
 
Animals treated with a higher dose of Ce.Cr 
(1000 mg/kg) showed liver tissue with central  
vein congestion and mild fatty change (Figure 
1D). In the Vo.Cr (500 mg/kg) treated animals 
the liver tissue showed periportal hepatocytes 
drop out, portal vein congestion with no fatty 
change (Figure 1E). Similar effects were 
observed with higher dose of Vo.Cr (1000 
mg/kg), Figure 1F. Atorvastatin (10 mg/kg) 
treated group showed central vein congestion 




This study demonstrates the anti-hyperlipidemic 
effect of Caralluma edulis and Verbena officinalis 
crude extract. Treatment with Ce.Cr extract and 
Vo.Cr extract lowered lipid profile and raised the 
HDL in mice. HFD-induced hyperlipidemia in 
mice causes increase in plasma TC, TGs, LDL, 
VLDL and oxidative damage in liver [16]. HFD 
induced hyperlipidemia decreases β-oxidation 
and increases the synthesis of cholesterol and 
oxidative stress due to decreased free radical 
scavenger enzymatic gene expression. Plant 
polyphenols plays a preventive role in 
cardiovascular diseases including atheroscle-
rosis. Combination of 0.25 - 0.5 % cholic acid 
with cholesterol increases cholesterol absorption 
and produces atherosclerosis in normal mice 
[17]. Cholic acid plays an important role in liver 
inflammation and lowers the production of bile 
acid and affects the TGs and HDL levels which 
further leads to development of atherosclerosis. 
Different types of fats are used to provide energy 
(20 – 60 %) derived from either using animal fats 
(beef tallow or lard) or plant fats oils (coconut or 
olive oil).  
 
Coconut oil, lard and olive oil cause hepatic 
steatosis without inflammation [18]. Mice fed with 
HFD increased the body weight compared to 
standard diet. HFD induced hepatic steatosis and 
inflammation begins with presence of leukocytes 
in the tissue. Hypercholesterolemia causes 
increase in the production of free radicals and 
raises levels of lipid peroxides [19]. Myristic acid 
and lauric acids are present in coconut oil; they 
increase level of LDL more than HDL. The 
elevation of the LDL level in animals fed on HFD 
could be related to changes in hepatic LDL 
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receptors. It also causes oxidative stress that 
further leads to increased oxidized LDL levels.  
 
Stress due to oxidation plays a very magnificent 
role in the development of cardiac complication, 
neurodegenerative diseases, and cancer and in 
the aging process. Flavonoids and terpenoids 
may reduce TC, TGs, LDL and VLDL through the 
inhibition of pancreatic lipases which are 
responsible for the conversion of triglyceride into 
fatty acids and glycerol [20]. Plants containing 
polyphenols inhibit lipid peroxidation and 
increases glutathione peroxidase which prevents 
tissue damage by neutralizing reactive oxygen 
species [21]. The total phenolic content of 
Verbena officinalis was 652.50 ± 2.36 Gallic Acid 
Equivalent (GAE g/kg dry mass). The total 
flavonoids contents were 188.90 ± 2.5 quercetin 
equivalents (QE g/kg of dry mass).  
 
The phenolic and flavonoid contents of these 
plants might have contributed to the observed 
beneficial effects on lipid profile in animals fed on 
HFD. The antioxidant inhibitory concentration 
was 15.76 ± 0.8 mg/L compared to vitamin C 4.4 
± 0.2 mg/L respectively. The anti-hyperlipdemic 
effect exhibited by Caralluma edulis may be 
related to its known antioxidant potential and in 
Verbena officinalis may be due to the presence 
of phytochemical compounds such as flavonoids, 
phenolic compounds, terpenoids, phenyl 
propanoids and iridoids, which were reported to 




The current study reveals that Caralluma edulis 
and Verbena officinalis crude extracts possess 
anti-hyperlipidemic potential against HFD-
induced hyperlipidemia. Further advanced 
studies were needed to identify the active 
principles accounting for anti-hyperlipidemic 
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